热门关键词:鸭脖娱乐  
当前位置:首页 > 关于我们 > 荣誉资质
研发“沉默杀手”克星|鸭脖娱乐平台
2020-11-01 [13469]

big pharma thinks it has spotted its next big opportunity-an un treatable silent killer that affects millions of people。大型制药企业指出,他们找到了以下根本:In recent months、large drug makers including allergan、Gilead and Novartis have collectively spent billions of dollars acquiions最近几个月,Allergan、Gilead、Novartis这种药物针对的是很少听说过的肝病——无酒精地方性肝炎(Nash)。

this advanced form of fatty liver disease causes scarring and inflamation of the liver and is thought to affect more than 16m people in the us,accc伯恩斯坦(Bernstein)表示,这种晚期脂肪肝疾病会导致肝疤痕和炎症,美国有超过1600万人患有这种疾病。In the most serious cases,the illness causes fatal cirrhosis,While also increasing a person ' s chances of developing liver cancer or headdrug makers are betting that the number of people with Nash-which is more common in overweight people-will rise dramatically in the coming ye制药企业希望,随着全球肥胖的流行,未来几年患有无酒精、地方性肝炎的人会出现戏剧性的下降(这种病在超载人口中更为常见)。

鸭脖娱乐

一些分析人士预测,治疗这种疾病的药品全球市场将超过每年350亿美元的最高值。there are no approved drugs to treat the condition but pharmaceutical groups are studying more than 25 experimental compounds in humans,With four尚未批准的症状药物有制药公司20 Of the large drug makers,allergan is furthest ahead,Having Spent $ 1.7 bn to acquire tobira,a San Francisco biotech groupTobira的主要药物Cenicriviroc将于今年年底转入第三期实验,预计首先在2019年得出结果。

Allergan recently Acquired another Smaller Nash-Focused Drug maker,Arkana,for $ 50m米。eljian最近投资5000万美元收购了非酒精性脂肪性肝炎药物规模较小的制药公司arra,“Nash is now the leading cause of liver Cirrhosis and cancer,having taken over from hepatitis c,”“and at the moment,there ' s nothing out there to treat it。”“非酒精性脂肪性肝炎尼科尔森博士回答说:“还有一些药没有得病。” “Gilead has entered the field too,recently acquiring nimbus for up to $ 1.2 bn,While also investing heavily in its internal research吉利德最近也花了至少12亿美元收购Nimbus,同时获得了投资内部研发工作的机会。

鸭脖娱乐

这家总部位于美国西海岸的生命科学技术公司已经在丙肝(另一种可怕的肝病)药物上进行了根本性的顺利。several other well-known pharmaceutical groups,including Novo Nordisk and Shire are working on Nash drugs at an earlier stage of developms howelopms但是,目前在这一领域取得第二大进展的两家公司是纽约生物技术集团Intercept Therapeutics和Shares In Intercept Jumped 13 Percent Last Week after the company Said it Had Redesigned A Late-stage Client上周,Intercept股价上涨了13%。此前,该公司宣布重新设计了Obeticholic ACID(Obeticholic ACID)的临床实验最终阶段,即Following Discussions with the us Food and Drug Administration,Intercept said the.the company would have had to prove the medicine could do both。

与美国食品药品监督管理局(FDA)讨论后,Intercept回应说,该药需要化疗或提高“肝纤维化”,此前该公司必须证明该药同时不具备这两种功效。intercept also said it would be able to analyse the data once it had enrolled 750 patients,rather than 1,400,After the process of recruitingthe changes reflect the flexibility of regulators at the FDA,Who want to encourage drug makers to invest in researching medicines for the un treaarch霍华德,The sluggish recruitment to intercept ' s trial is indicative of one of The biggest hurdles facing Nash drug makers 3360 The disease is very dis但有人指出,Intercept在招募参与实验的患者方面进展缓慢,开发非酒精性脂肪性肝炎药物的制药企业仅次于障碍之一。

这种疾病是很难临床的。the vast majority of people do not realise they have the " silent " disease,which only causes symp toms such as jaundice,Fatigue and大多数人没有意识到他们得了这种“绝望”病,即使这种疾病进行到晚期,患者的症状也只有黄疸、疲劳和减肥。doctors some times suspect a patient has Nash when they have elevated liver enzymes in their blood or when they spot abnormalities during ultra sound ss患者血液中的肝酶水平升高或超声波检查发现异常时,医生有时不会推测患者患有这种疾病。

but the only surefire way of diagnosing the disease is to carry out a liver biopsy-a complex,Invasive procedure that requires an anaesthetion在极少数情况下,前列腺会引起需要器官移植或外科手术的炎症。many patients are reluctant to undergo the procedure,which poses a difficulty not just for recruiting them to clinical trials,But also很多患者不愿意接受前列腺也就是说,在现实世界中,为了确认人们是否患上这种病,不能说服他们拒绝检查。

鸭脖娱乐官方网站

drug makers are hoping that less invasive tests will be developed that use biological clues or " biomarkers " to diagnose the disease without制药企业期待开发利用生物线索(即“生物标记”)的非侵入性检查方法来临床该疾病,因此仍然需要前列腺。“we really believe that there will be breakthroughs that will make it much easier for physicians to diagnose the disease and subse quently to ution E“我们相信医生们不会取得突破性的突破,使这种疾病更容易临床。

并且充分利用目前正在开发的药物。”埃尔根的尼科尔森博士说。

One option is a simple breath test,according to dr Ilan yaron,chief medical officer of tiz pharma,A London-based biotech group the“the FDA does not recognise thest ts yet,But it will in time,”he says。“选项之一是进行非常简单的排便检查,开始对该病药进行人体实验的伦敦生物技术公司Tiz Pharma首席医疗官一职?雅龙(Ilan Yaron)表示:“美国食品药品监督管理局目前还不接受这种检查方法,但以后不会接受。

”However,even if drug makers find a reliable,non-invasive way of diagnosing the disease,Thereis no guarantee that Nash sufferers will但是,即使制药公司找到可靠的非入侵临床方法,也不能保证该患者不竞争服药。the disease progresses slowly and many sufferers will die of something else;Given the lack of symptoms,people could be wary of taking a drug for life when they feel perfectly well。

这种疾病发展缓慢,很多患者不会死于其他原因。考虑到症状少,心情好的时候要一辈子服用一种药,可以保持警惕。I ' m sceptical as to whether this is actually needed for most people,“says ronny gal,Analyst at Bernstein。

鸭脖娱乐平台

“you ' re essentially trying to put into chronic treatment forever a broad population that will probably never dever Rious form of the disease .”我想大部分人都知道这是必要的。“伯恩斯坦分析师罗尼?加尔(Ronny Gal)回答说:“很多人正在试图永久拒绝慢性化疗,他们的疾病最终很有可能发展到最严重的水平。

”(威廉莎士比亚,北方执行部队。)cash-strapped health care systems could resist paying for the drugin all but the sickest patients,Predicts Mr gal . these number approximation在美国,这些患者的人数约为150万。

For that reason,he believes the market for Nash drugs will be much smaller than many others on wall street are expecting,And is pencilling in因此,他指出,该病的市场将远远超过华尔街其他许多分析师。对于他称之为“中等疾病”的这种“中等疾病”,他预计销售额最高值将超过80亿美元。“if you take all The people with advanced Nash and ask how many people will end up becoming seriously ill in their life times,The number could actimes”:鸭脖娱乐官方网站。

本文来源:鸭脖娱乐-www.healthmedic365.com